FCM
EW icon

Fourpath Capital Management’s Edwards Lifesciences EW Stock Holding History

Fourpath Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-492
Closed -$32.5K – 413
2024
Q3 		$32.5K Buy
+492
New +$35.7K 0.01% 382

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Fourpath Capital Management's EW Position: Q4 2024 in Review

Fourpath Capital Management sold out of Edwards Lifesciences (EW) in Q4 2024, closing a stake of 492 shares — an estimated $32.5K sold.

Fourpath Capital Management first reported a position in EW in Q3 2024 and held it in 1 quarter. The position peaked at $32.5K in Q3 2024. 1,229 funds tracked by Wall St. Rank hold EW as of Q4 2024.

  • Fourpath Capital Management reported no remaining Edwards Lifesciences position as of Q4 2024 after selling out during the quarter.
  • Fourpath Capital Management sold 492 Edwards Lifesciences shares in Q4 2024, an estimated $32.5K.
  • Fourpath Capital Management first reported a position in Edwards Lifesciences in Q3 2024 and held it in 1 quarter.
  • Fourpath Capital Management's Edwards Lifesciences position peaked at $32.5K in Q3 2024.
  • 1,229 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2024.

Based on Fourpath Capital Management's 13F filing for Q4 2024, filed 24 Jan 2025.